Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Short-Term Debt issuancesShort-Term Debt repayments
Ratios

Myriad Genetics (MYGN) Short-Term Debt repayments (2017 - 2025)

Historic Short-Term Debt repayments for Myriad Genetics (MYGN) over the last 7 years, with Q3 2025 value amounting to $60.0 million.

  • Myriad Genetics' Short-Term Debt repayments rose 20000.0% to $60.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $100.0 million, marking a year-over-year decrease of 2857.14%. This contributed to the annual value of $119.5 million for FY2024, which is 19875.0% up from last year.
  • As of Q3 2025, Myriad Genetics' Short-Term Debt repayments stood at $60.0 million, which was up 20000.0% from $20.5 million recorded in Q1 2025.
  • Myriad Genetics' Short-Term Debt repayments' 5-year high stood at $106.4 million during Q3 2021, with a 5-year trough of $19.5 million in Q4 2024.
  • For the 4-year period, Myriad Genetics' Short-Term Debt repayments averaged around $46.6 million, with its median value being $45.0 million (2021).
  • Within the past 5 years, the most significant YoY rise in Myriad Genetics' Short-Term Debt repayments was 20000.0% (2025), while the steepest drop was 6583.33% (2025).
  • Myriad Genetics' Short-Term Debt repayments (Quarter) stood at $106.4 million in 2021, then plummeted by 62.41% to $40.0 million in 2023, then plummeted by 51.25% to $19.5 million in 2024, then skyrocketed by 207.69% to $60.0 million in 2025.
  • Its Short-Term Debt repayments was $60.0 million in Q3 2025, compared to $20.5 million in Q1 2025 and $19.5 million in Q4 2024.